ECZEMA THERAPEUTICS MARKET ANALYSIS

Eczema Therapeutics Market, by Treatment (Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin inhibitors, Antibiotics, Immunomodulators, and Interleukin inhibitors), by Distribution Channel (Hospital and Clinics, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Sep 2021
Code : CMI4630
Pages :176
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Eczema Therapeutics Market – Restraints

Increasing delays in the drug approvals from the regulatory authorities for the treatment of eczema is expected to increase the growth of the global eczema therapeutics market over the forecast period. For instance, on June 16, 2021, the U.S. Food and Drug Administration (U.S. FDA) delayed further decisions for AbbVie Inc.’s Rinvoq and Eli Lily and Company’s Olumiant, which have been indicated for the treatment of moderate to severe atopic dermatitis. The drugs belong to the JAK class of medicines, and the medicines from this drug class has been associated with severe side effects such as blood clots, cancers etc.

The termination of the clinical trials, which was directed for the development of the drug for eczema, is expected to hamper the growth of the market over the forecast period. For instance, in 2019, Galapagos NV and MorphoSys AG ended their agreement with Novartis AG for the development of the drug MOR106, which was directed for the development for the atopic dermatitis. Novartis AG reported negative results during the Phase II trial for MOR106. The above factors are expected to restrain the growth of the global eczema therapeutics market over the forecast period.